Dacomitinib

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Penile Neoplasms

Conditions

Penile Neoplasms, Carcinoma, Squamous Cell

Trial Timeline

Jun 15, 2013 → Sep 21, 2018

NCT ID

NCT01728233

About Dacomitinib

Dacomitinib is a phase 2 stage product being developed by Pfizer for Penile Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01728233. Target conditions include Penile Neoplasms, Carcinoma, Squamous Cell.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04609319	Pre-clinical	Completed	Jun 11, 2021	May 28, 2024	Lung Cancer
NCT04511533	Approved	Completed	Aug 27, 2020	Nov 8, 2022	Metastatic Non Small Cell Lung Cancer
NCT04027647	Phase 2	Active	Sep 11, 2019	Mar 31, 2026	NSCLC Stage IIIB
NCT03865446	Phase 1	Completed	Apr 5, 2019	Oct 24, 2019	Severe Hepatic Impairment
NCT02382796	Phase 2	Completed	Jul 10, 2015	May 30, 2019	NSCLC
NCT02097433	Phase 1	Completed	Jul 1, 2014	Sep 1, 2014	Healthy
NCT02047747	Phase 2	Terminated	Feb 1, 2014	Feb 1, 2016	Brain Cancer
NCT01728233	Phase 2	Completed	Jun 15, 2013	Sep 21, 2018	Penile Neoplasms

Competing Products

8 competing products in Penile Neoplasms

See all competitors

Product	Company	Stage	Hype Score
Avelumab + enfortumab vedotin	Astellas Pharma	Phase 2	52
Pembrolizumab + Standard of care therapy	Merck	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
Arm A: Atezolizumab and Radiotherapy + Arm B: Atezolizumab	Roche	Phase 2	52
Placebo QHS and sildenafil and questionnaires + Sildenafil and questionnaire + Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires	Pfizer	Pre-clinical	22
Avelumab	Pfizer	Phase 2	51
Cabazitaxel	Sanofi	Phase 2	51
Retifanlimab	Incyte	Phase 2	49

Other Products from Pfizer